Grail (GRAL) shares were over 44% lower in recent Friday premarket activity, a day after the company said its NHS-Galleri trial missed its primary Stage III and IV cancer reduction endpoint.
Akamai Technologies (AKAM) stock was down nearly 11% after the company issued overnight lower-than-expected Q1 and 2026 non-GAAP earnings guidance.
Chemours (CC) stock was down more than 9%, a day after the company posted lower Q4 adjusted EPS and sales.
Hudbay Minerals (HBM) shares were 3% lower after the company reported lower-than-expected Q4 adjusted EPS and revenue.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.